ArticleThoracic cancer2025
Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- miR-142-3p in cancer: intracellular tumor suppression and extracellular vesicle- mediated microenvironmental signaling.Molecular biology reports · 2026Review
- Unacylated ghrelin counteracts mitochondrial dysfunction and neuromuscular junction disruption in cancer cachexia.American journal of physiology. Cell physiology · 2026Article
- Patterns, causes, and clinical impact of treatment interruption on early outcomes in patients receiving radiotherapy for lung cancer: a retrospective study.Frontiers in oncology · 2026Article
- Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCachexia is a syndrome in patients with cancer that reduces life quality and prognosis, characterized by severe weight loss, muscle atrophy, and anorexia. How cachexia adversely affects older patients with small cell lung cancer (SCLC) remains uncertain. This study aimed to determine the effect of cachexia on prognosis, treatment delivery, and efficacy in older patients with advanced SCLC receiving first-line platinum-based chemotherapy.
methodWe retrospectively analyzed older patients (≥ 70 years) with advanced SCLC treated with carboplatin and etoposide between January 2015 and June 2020 at the Shizuoka Cancer Center. Cachexia was diagnosed based on the % weight loss and body mass index. After excluding patients with no documented weight change and those who relapsed after radiotherapy, we examined the effect of cachexia on treatment delivery, progression-free survival (PFS), and overall survival (OS).
resultsCachexia was identified in 57% (28 of 49) of patients. The cachexia group experienced more frequent treatment interruptions and dose reductions than the non-cachexia group (46% vs. 10% for dose reductions, p < 0.05; 61% vs. 90% for completion of four chemotherapy courses, p < 0.05). Median PFS and OS were significantly shorter in the cachexia group compared to those in the non-cachexia group (PFS: 3.3 vs. 5.4 months; OS: 6.3 vs. 15.1 months).
conclusionOlder patients with advanced SCLC and cachexia undergoing carboplatin and etoposide therapy exhibited shorter PFS and OS than those without cachexia. Treatment delivery was less effective in the cachexia group than in the non-cachexia group, suggesting that their vulnerabilities affected treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.